EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial

Writing Committee for the REMAP-CAP Investigators, Alisa M Higgins, Lindsay R Berry, Elizabeth Lorenzi, Srinivas Murthy, Zoe McQuilten, Paul R Mouncey, Farah Al-Beidh, Djillali Annane, Yaseen M Arabi, Abi Beane, Wilma van Bentum-Puijk und 48 weitere

JAMA · 2023

DOI: 10.1001/jama.2022.23257 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA, 2023. Verfasst von Writing Committee for the REMAP-CAP Investigators und 59 weiteren Autor:innen. Beteiligte Einrichtung: Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 119-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Chief Scientist Office, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown.

Objective

To determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes. Design, Setting, and Participants Prespecified secondary analysis of an ongoing adaptive platform trial (REMAP-CAP) testing interventions within multiple therapeutic domains in which 4869 critically ill adult patients with COVID-19 were enrolled between March 9, 2020, and June 22, 2021, from 197 sites in 14 countries. The final 180-day follow-up was completed on March 2, 2022.

Interventions

Patients were randomized to receive 1 or more interventions within 6 treatment domains: immune modulators (n = 2274), convalescent plasma (n = 2011), antiplatelet therapy (n = 1557), anticoagulation (n = 1033), antivirals (n = 726), and corticosteroids (n = 401). Main Outcomes and Measures The main outcome was survival through day 180, analyzed using a bayesian piecewise exponential model. A hazard ratio (HR) less than 1 represented improved survival (superiority), while an HR greater than 1 represented worsened survival (harm); futility was represented by a relative improvement less than 20% in outcome, shown by an HR greater than 0.83.

Results

Among 4869 randomized patients (mean age, 59.3 years; 1537 [32.1%] women), 4107 (84.3%) had known vital status and 2590 (63.1%) were alive at day 180. IL-6 receptor antagonists had a greater than 99.9% probability of improving 6-month survival (adjusted HR, 0.74 [95% credible interval {CrI}, 0.61-0.90]) and antiplatelet agents had a 95% probability of improving 6-month survival (adjusted HR, 0.85 [95% CrI, 0.71-1.03]) compared with the control, while the probability of trial-defined statistical futility (HR >0.83) was high for therapeutic anticoagulation (99.9%; HR, 1.13 [95% CrI, 0.93-1.42]), convalescent plasma (99.2%; HR, 0.99 [95% CrI, 0.86-1.14]), and lopinavir-ritonavir (96.6%; HR, 1.06 [95% CrI, 0.82-1.38]) and the probabilities of harm from hydroxychloroquine (96.9%; HR, 1.51 [95% CrI, 0.98-2.29]) and the combination of lopinavir-ritonavir and hydroxychloroquine (96.8%; HR, 1.61 [95% CrI, 0.97-2.67]) were high. The corticosteroid domain was stopped early prior to reaching a predefined statistical trigger; there was a 57.1% to 61.6% probability of improving 6-month survival across varying hydrocortisone dosing strategies. Conclusions and Relevance Among critically ill patients with COVID-19 randomized to receive 1 or more therapeutic interventions, treatment with an IL-6 receptor antagonist had a greater than 99.9% probability of improved 180-day mortality compared with patients randomized to the control, and treatment with an antiplatelet had a 95.0% probability of improved 180-day mortality compared with patients randomized to the control. Overall, when considered with previously reported short-term results, the findings indicate that initial in-hospital treatment effects were consistent for most therapies through 6 months.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19AdultHumansFemaleMiddle AgedMaleLopinavirRitonavirFollow-Up StudiesHydroxychloroquineSARS-CoV-2Critical IllnessBayes TheoremCOVID-19 SerotherapyAdrenal Cortex HormonesAnticoagulantsReceptors, Interleukin-6Adaptive Clinical Trials as Topic

Substanzen

LopinavirRitonavirHydroxychloroquineAdrenal Cortex HormonesAnticoagulantsReceptors, Interleukin-6

Autor:innen und Institutionen

  • Monash University, Melbourne, Victoria, Australia.
  • Berry Consultants, Austin, Texas.
  • University of British Columbia, Vancouver, British Columbia, Canada.
  • Monash Health, Melbourne, Victoria, Australia.
  • Intensive Care National Audit & Research Centre (ICNARC), London, United Kingdom.
  • Imperial College London, London, United Kingdom.

Förderung

  • Chief Scientist Office
  • NIGMS NIH HHS

Zitieren

APA

Writing Committee for the REMAP-CAP Investigators, Higgins, A. M., Berry, L. R., Lorenzi, E., Murthy, S., McQuilten, Z., Mouncey, P. R., Al-Beidh, F., Annane, D., Arabi, Y. M., Beane, A., van Bentum-Puijk, W., Bhimani, Z., Bonten, M. J. M., Bradbury, C. A., Brunkhorst, F. M., Burrell, A., Buzgau, A., Buxton, M., …, & Lewis, R. J. (2023). Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2022.23257

Vancouver

Writing Committee for the REMAP-CAP Investigators, Higgins AM, Berry LR, Lorenzi E, Murthy S, McQuilten Z, et al. Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. JAMA. 2023. doi:10.1001/jama.2022.23257

BibTeX
@article{WritingCommitteefortheREMAPCAPInvestigators2023,
  author = {Writing Committee for the REMAP-CAP Investigators, Writing Committee for the REMAP-CAP Investigators and Higgins, Alisa M and Berry, Lindsay R and Lorenzi, Elizabeth and Murthy, Srinivas and McQuilten, Zoe and Mouncey, Paul R and Al-Beidh, Farah and Annane, Djillali and Arabi, Yaseen M and Beane, Abi and van Bentum-Puijk, Wilma and Bhimani, Zahra and Bonten, Marc J M and Bradbury, Charlotte A and Brunkhorst, Frank M and Burrell, Aidan and Buzgau, Adrian and Buxton, Meredith and Charles, Walton N and Cove, Matthew and Detry, Michelle A and Estcourt, Lise J and Fagbodun, Elizabeth O and Fitzgerald, Mark and Girard, Timothy D and Goligher, Ewan C and Goossens, Herman and Haniffa, Rashan and Hills, Thomas and Horvat, Christopher M and Huang, David T and Ichihara, Nao and Lamontagne, Francois and Marshall, John C and McAuley, Daniel F and McGlothlin, Anna and McGuinness, Shay P and McVerry, Bryan J and Neal, Matthew D and Nichol, Alistair D and Parke, Rachael L and Parker, Jane C and Parry-Billings, Karen and Peters, Sam E C and Reyes, Luis F and Rowan, Kathryn M and Saito, Hiroki and Santos, Marlene S and Saunders, Christina T and Serpa-Neto, Ary and Seymour, Christopher W and Shankar-Hari, Manu and Stronach, Lucy M and Turgeon, Alexis F and Turner, Anne M and van de Veerdonk, Frank L and Zarychanski, Ryan and Green, Cameron and Lewis, Roger J},
  title = {Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial},
  journal = {JAMA},
  year = {2023},
  doi = {10.1001/jama.2022.23257}
}
Kostenlos starten →